These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1314874)

  • 1. Prophylaxis of cytomegalovirus disease in allogeneic bone marrow transplantation.
    Grigg A; Phillips G
    J Infect Dis; 1992 May; 165(5):972-3. PubMed ID: 1314874
    [No Abstract]   [Full Text] [Related]  

  • 2. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
    Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
    Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of cytomegalovirus prophylaxis in renal retransplantation.
    Singh TP; Gruber SA; Lempert N; Freed B; Conti DJ
    Transplant Proc; 1995 Feb; 27(1):964-5. PubMed ID: 7879247
    [No Abstract]   [Full Text] [Related]  

  • 4. Cytomegalovirus prophylaxis and treatment following bone marrow transplantation.
    Tsinontides AC; Bechtel TP
    Ann Pharmacother; 1996 Nov; 30(11):1277-90. PubMed ID: 8913411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation.
    Winston DJ; Yeager AM; Chandrasekar PH; Snydman DR; Petersen FB; Territo MC;
    Clin Infect Dis; 2003 Mar; 36(6):749-58. PubMed ID: 12627359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CMV prophylaxis in allogeneic BMT with ganciclovir and CMV immune globulin.
    Patton WN; Carter C; Bienz N; Lamb T; Boughton BJ; Franklin IM
    Bone Marrow Transplant; 1991; 7 Suppl 2():44. PubMed ID: 1652330
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
    Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF
    Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancytopenia in allogeneic marrow transplant recipients: role of cytomegalovirus.
    Bilgrami S; Almeida GD; Quinn JJ; Tuck D; Bergstrom S; Dainiak N; Poliquin C; Ascensao JL
    Br J Haematol; 1994 Jun; 87(2):357-62. PubMed ID: 7947279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus infection in marrow transplantation.
    Boeckh M; Bowden R
    Cancer Treat Res; 1995; 76():97-136. PubMed ID: 7577347
    [No Abstract]   [Full Text] [Related]  

  • 10. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation.
    Goodrich JM; Mori M; Gleaves CA; Du Mond C; Cays M; Ebeling DF; Buhles WC; DeArmond B; Meyers JD
    N Engl J Med; 1991 Dec; 325(23):1601-7. PubMed ID: 1658652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group.
    Ljungman P; Engelhard D; Link H; Biron P; Brandt L; Brunet S; Cordonnier C; Debusscher L; de Laurenzi A; Kolb HJ
    Clin Infect Dis; 1992 Apr; 14(4):831-5. PubMed ID: 1315585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-emptive ganciclovir treatment can play a role in restoration of hematopoiesis after allogeneic bone marrow transplantation.
    Choi JH; Kim DW; Cho SG; Yoo JH; Jeong DC; Han CW; Shin WS; Min WS; Kim HK; Kim CC; Kim DJ
    Bone Marrow Transplant; 1997 Jan; 19(2):187-90. PubMed ID: 9116619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group.
    Schmidt GM; Horak DA; Niland JC; Duncan SR; Forman SJ; Zaia JA
    N Engl J Med; 1991 Apr; 324(15):1005-11. PubMed ID: 1848679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis of cytomegalovirus infection after bone marrow transplantation.
    Schmidt GM
    Semin Oncol; 1992 Jun; 19(3 Suppl 7):20-6. PubMed ID: 1319612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CMV prophylaxis: what is valid in 2002?
    Heemann U; Wenzel RR
    Nephrol Dial Transplant; 2002 Apr; 17(4):556-9. PubMed ID: 11917045
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
    Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus prophylaxis with ganciclovir, acyclovir, and CMV hyperimmune globulin in liver transplant patients receiving OKT3 induction.
    Ham JM; Shelden SL; Godkin RR; Posner MP; Fisher RA
    Transplant Proc; 1995 Oct; 27(5 Suppl 1):31-3. PubMed ID: 7482814
    [No Abstract]   [Full Text] [Related]  

  • 18. Prophylaxis of CMV infection after BMT.
    Zaia JA; Schmidt GM
    Bone Marrow Transplant; 1992; 10 Suppl 1():139-43. PubMed ID: 1325854
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment and prophylaxis of cytomegalovirus disease: a commentary.
    Yee GC
    Pharmacotherapy; 1993; 13(2):167; discussion 168. PubMed ID: 8385774
    [No Abstract]   [Full Text] [Related]  

  • 20. Ganciclovir and the prevention of CMV disease after allogeneic BMT: policy at the Hammersmith Hospital.
    Ward KN; Roberts IA; van Rhee F
    Bone Marrow Transplant; 1994 Feb; 13(2):230-1. PubMed ID: 8205098
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.